<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35563653</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves' Orbitopathy.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">5261</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23095261</ELocationID>
        <Abstract>
          <AbstractText>Fibrosis of extraocular muscles (EOMs) is a marker of end-stage in Graves' orbitopathy (GO). To determine the antifibrotic and anti-inflammatory therapeutic effects and the underlying molecular mechanisms of disulfiram (DSF) on perimysial orbital fibroblasts (pOFs) in a GO model in vitro, primary cultures of pOFs from eight patients with GO and six subjects without GO (NG) were established. CCK-8 and EdU assays, IF, qPCR, WB, three-dimensional collagen gel contraction assays, cell scratch experiments, and ELISAs were performed. After TGF-β1 stimulation of pOFs, the proliferation rate of the GO group but not the NG group increased significantly. DSF dose-dependently inhibited the proliferation, contraction, and migration of pOFs in the GO group. Additionally, DSF dose-dependently inhibited fibrosis and extracellular matrix production markers (FN1, COL1A1, α-SMA, CTGF) at the mRNA and protein levels. Furthermore, DSF mediates antifibrotic effects on GO pOFs partially through the ERK-Snail signaling pathway. In addition, DSF attenuated HA production and suppressed inflammatory chemokine molecule expression induced by TGF-β1 in GO pOFs. In this in vitro study, we demonstrate the inhibitory effect of DSF on pOFs fibrosis in GO, HA production, and inflammation. DSF may be a potential drug candidate for preventing and treating tissue fibrosis in GO.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xing</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-7345-7269</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Huijing</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-8091-8457</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Shenglan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sha</LastName>
            <ForeName>Xiaotong</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-0576-0987</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiandai</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Te</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Rongxin</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Huasheng</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>TR3MLJ1UAI</RegistryNumber>
          <NameOfSubstance UI="D004221">Disulfiram</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004221" MajorTopicYN="N">Disulfiram</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="Y">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Graves’ orbitopathy</Keyword>
        <Keyword MajorTopicYN="N">disulfiram</Keyword>
        <Keyword MajorTopicYN="N">fibrosis</Keyword>
        <Keyword MajorTopicYN="N">myofibroblasts</Keyword>
        <Keyword MajorTopicYN="N">perimysial orbital fibroblasts</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. </CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35563653</ArticleId>
        <ArticleId IdType="pmc">PMC9104881</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms23095261</ArticleId>
        <ArticleId IdType="pii">ijms23095261</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wakelkamp I.M., Baldeschi L., Saeed P., Mourits M., Prummel M.F., Wiersinga W.M. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves’ ophthalmopathy? A randomized controlled trial. Clin. Endocrinol. 2005;63:323–328. doi: 10.1111/j.1365-2265.2005.02345.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2005.02345.x</ArticleId>
            <ArticleId IdType="pubmed">16117821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith T.J., Koumas L., Gagnon A., Bell A., Sempowski G.D., Phipps R.P., Sorisky A. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 2002;87:385–392. doi: 10.1210/jcem.87.1.8164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.87.1.8164</ArticleId>
            <ArticleId IdType="pubmed">11788681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu L., Port M., Landi S., Gemignani F., Cipollini M., Elisei R., Goudeva L., Müller J.A., Nerlich K., Pellegrini G., et al.  Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves’ ophthalmopathy. Thyroid. 2008;18:1291–1296. doi: 10.1089/thy.2008.0255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2008.0255</ArticleId>
            <ArticleId IdType="pmc">PMC2857447</ArticleId>
            <ArticleId IdType="pubmed">18976167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Fernandez F., Bevilacqua T., Lee K.I., Chandrashekar R., Hsu L., Garlipp M.A., Griswold J.B., Crouch R.K., Ghosh D. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: A potential treatment for Graves’ ophthalmopathy. Investig. Ophthalmol. Vis. Sci. 2009;50:3091–3098. doi: 10.1167/iovs.08-2443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.08-2443</ArticleId>
            <ArticleId IdType="pubmed">19234339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai C.C., Wu S.B., Kao S.C., Kau H.C., Lee F.L., Wei Y.H. The protective effect of antioxidants on orbital fibroblasts from patients with Graves’ ophthalmopathy in response to oxidative stress. Mol. Vis. 2013;19:927–934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3654843</ArticleId>
            <ArticleId IdType="pubmed">23687429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell R.G., Smith H.W. Preliminary report on clinical trials of antabuse. Can. Med. Assoc. J. 1949;60:286–288.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu T., Wang P., Cong M., Zhao X., Zhang D., Xu H., Liu L., Jia J., You H. Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. Br. J. Pharmacol. 2018;175:4480–4495. doi: 10.1111/bph.14503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.14503</ArticleId>
            <ArticleId IdType="pmc">PMC6255958</ArticleId>
            <ArticleId IdType="pubmed">30266038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Chen F., Chen J., Chan S., He Y., Liu W., Zhang G. Disulfiram/copper induces antitumor activity against both nasopharyngeal cancer cells and cancer-associated fibroblasts through ROS/MAPK and ferroptosis pathways. Cancers. 2020;12:138.  doi: 10.3390/cancers12010138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12010138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Zhang R., Han X. Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. Inflamm. Res. 2021;70:543–552. doi: 10.1007/s00011-021-01457-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-021-01457-y</ArticleId>
            <ArticleId IdType="pubmed">33851234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fillmore N., Bell S., Shen C., Nguyen V., La J., Dubreuil M., Strymish J., Brophy M., Mehta G., Wu H., et al.  Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. PLoS ONE. 2021;16:e0259061.  doi: 10.1371/journal.pone.0259061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0259061</ArticleId>
            <ArticleId IdType="pmc">PMC8553043</ArticleId>
            <ArticleId IdType="pubmed">34710137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adrover J.M., Carrau L., Daßler-Plenker J., Bram Y., Chandar V., Houghton S., Redmond D., Merrill J.R., Shevik M. Disulfiram inhibits neutrophil extracellular trap formation protecting rodents from acute lung injury and SARS-CoV-2 infection. JCI Insight. 2022;7:e157342. doi: 10.1172/jci.insight.157342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.157342</ArticleId>
            <ArticleId IdType="pmc">PMC8983145</ArticleId>
            <ArticleId IdType="pubmed">35133984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahadome S.D., Abraham D.J., Rayapureddi S., Saw V.P., Saban D.R., Calder V.L., Norman J.T., Ponticos M., Daniels J.T., Dart J.K. Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring. JCI Insight. 2016;1:e87001. doi: 10.1172/jci.insight.87001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.87001</ArticleId>
            <ArticleId IdType="pmc">PMC5033866</ArticleId>
            <ArticleId IdType="pubmed">27699226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y., Li H., Chen X., Yang H., Guan H., He X., Chen Y., Pokharel S., Xiao H., Li Y. Novel roles of chloroquine and hydroxychloroquine in graves’ orbitopathy therapy by targeting orbital fibroblasts. J. Clin. Endocrinol. Metab. 2020;105:1906–1917. doi: 10.1210/clinem/dgaa161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/clinem/dgaa161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Agha E., Kramann R., Schneider R.K., Li X., Seeger W., Humphreys B.D., Bellusci S. Mesenchymal stem cells in fibrotic disease. Cell Stem Cell. 2017;21:166–177. doi: 10.1016/j.stem.2017.07.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2017.07.011</ArticleId>
            <ArticleId IdType="pubmed">28777943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koumas L., Smith T.J., Feldon S., Blumberg N., Phipps R.P. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am. J. Pathol. 2003;163:1291–1300. doi: 10.1016/S0002-9440(10)63488-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)63488-8</ArticleId>
            <ArticleId IdType="pmc">PMC1868289</ArticleId>
            <ArticleId IdType="pubmed">14507638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Force T., Bonventre J.V. Growth factors and mitogen-activated protein kinases. Hypertension. 1998;31:152–161. doi: 10.1161/01.HYP.31.1.152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.HYP.31.1.152</ArticleId>
            <ArticleId IdType="pubmed">9453296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K., Song Y., Xu G., Ye J., Wu Z., Liu X., Dong X., Zhang M., Xing Y., Zhu S., et al.  Conbercept for treatment of neovascular age-related macular degeneration: Results of the randomized phase 3 PHOENIX study. Am. J. Ophthalmol. 2019;197:156–167. doi: 10.1016/j.ajo.2018.08.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajo.2018.08.026</ArticleId>
            <ArticleId IdType="pubmed">30148987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith T., Bahn R., Gorman C. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr. Rev. 1989;10:366–391. doi: 10.1210/edrv-10-3-366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/edrv-10-3-366</ArticleId>
            <ArticleId IdType="pubmed">2673756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith T.J., Kahaly G.J., Ezra D.G., Fleming J.C., Dailey R.A., Tang R.A., Harris G.J., Antonelli A., Salvi M., Goldberg R.A., et al.  Teprotumumab for thyroid-associated ophthalmopathy. N. Engl. J. Med. 2017;376:1748–1761. doi: 10.1056/NEJMoa1614949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1614949</ArticleId>
            <ArticleId IdType="pmc">PMC5718164</ArticleId>
            <ArticleId IdType="pubmed">28467880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douglas R.S., Kahaly G.J., Patel A., Sile S., Thompson E.H., Perdok R., Fleming J.C., Fowler B.T., Marcocci C., Marinò M., et al.  Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 2020;382:341–352. doi: 10.1056/NEJMoa1910434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910434</ArticleId>
            <ArticleId IdType="pubmed">31971679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vannucchi G., Campi I., Covelli D., Currò N., Lazzaroni E., Palomba A., Soranna D., Zambon A., Fugazzola L., Muller I., et al.  Efficacy profile and safety of very low-dose rituximab in patients with graves’ orbitopathy. Thyroid. 2021;31:821–828. doi: 10.1089/thy.2020.0269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2020.0269</ArticleId>
            <ArticleId IdType="pubmed">33234032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayabe R., Rootman D.B., Hwang C.J., Ben-Artzi A., Goldberg R. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast. Reconstr. Surg. 2014;30:415–419. doi: 10.1097/IOP.0000000000000211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/IOP.0000000000000211</ArticleId>
            <ArticleId IdType="pubmed">24978425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durrani O.M., Reuser T.Q., Murray P.I. Infliximab: A novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit. 2005;24:117–119. doi: 10.1080/01676830590912562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/01676830590912562</ArticleId>
            <ArticleId IdType="pubmed">16191800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-Bilbao L., Martínez-López D., Revenga M., López-Vázquez Á., Valls-Pascual E., Atienza-Mateo B., Valls-Espinosa B., Maiz-Alonso O., Blanco A., Torre-Salaberri I., et al.  Anti-IL-6 receptor tocilizumab in refractory graves’ orbitopathy: National multicenter observational study of 48 patients. J. Clin. Med. 2020;9:2816.  doi: 10.3390/jcm9092816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm9092816</ArticleId>
            <ArticleId IdType="pmc">PMC7563792</ArticleId>
            <ArticleId IdType="pubmed">32878150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérez-Moreiras J.V., Varela-Agra M., Prada-Sánchez M.C., Prada-Ramallal G. Steroid-resistant graves’ orbitopathy treated with tocilizumab in real-world clinical practice: A 9-year single-center experience. J. Clin. Med. 2021;10:706.  doi: 10.3390/jcm10040706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm10040706</ArticleId>
            <ArticleId IdType="pmc">PMC7916878</ArticleId>
            <ArticleId IdType="pubmed">33670151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reich K., Warren R.B., Lebwohl M., Gooderham M., Strober B., Langley R.G., Paul C., De Cuyper D., Vanvoorden V., Madden C., et al.  Bimekizumab versus Secukinumab in plaque psoriasis. N. Engl. J. Med. 2021;385:142–152. doi: 10.1056/NEJMoa2102383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2102383</ArticleId>
            <ArticleId IdType="pubmed">33891380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Virakul S., van Steensel L., Dalm V.A., Paridaens D., van Hagen P.M., Dik W.A. Platelet-derived growth factor: A key factor in the pathogenesis of graves’ ophthalmopathy and potential target for treatment. Eur. Thyroid J. 2014;3:217–226. doi: 10.1159/000367968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000367968</ArticleId>
            <ArticleId IdType="pmc">PMC4311307</ArticleId>
            <ArticleId IdType="pubmed">25759797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S.B., Hou T.Y., Kau H.C., Tsai C.C. Effect of pirfenidone on TGF-beta1-induced myofibroblast differentiation and extracellular matrix homeostasis of human orbital fibroblasts in graves’ ophthalmopathy. Biomolecules. 2021;11:1424.  doi: 10.3390/biom11101424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom11101424</ArticleId>
            <ArticleId IdType="pmc">PMC8533421</ArticleId>
            <ArticleId IdType="pubmed">34680057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon J.S., Chae M.K., Jang S.Y., Lee S.Y., Lee E.J. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves’ orbitopathy. Investig. Ophthalmol. Vis. Sci. 2012;53:5921–5929. doi: 10.1167/iovs.12-9646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.12-9646</ArticleId>
            <ArticleId IdType="pubmed">22871832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y.H., Liao S.L., Wang S.H., Wang C.C., Yang C.H. Simvastatin and ROCK inhibitor Y-27632 inhibit myofibroblast differentiation of graves’ ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways. Front. Endocrinol. 2020;11:607968. doi: 10.3389/fendo.2020.607968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2020.607968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu W.K., Hwang W.L., Wang Y.C., Tsai C.C., Wei Y.H. Curcumin suppresses TGF-beta1-induced myofibroblast differentiation and attenuates angiogenic activity of orbital fibroblasts. Int. J. Mol. Sci. 2021;22:6829.  doi: 10.3390/ijms22136829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22136829</ArticleId>
            <ArticleId IdType="pmc">PMC8268269</ArticleId>
            <ArticleId IdType="pubmed">34202024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma R., Ren H., Xu B., Cheng Y., Gan L., Zhang R., Wu J., Qian J. PH20 inhibits TGFbeta1-induced differentiation of perimysial orbital fibroblasts via hyaluronan-CD44 pathway in thyroid-associated ophthalmopathy. Investig. Ophthalmol. Vis. Sci. 2019;60:1431–1441. doi: 10.1167/iovs.18-26268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.18-26268</ArticleId>
            <ArticleId IdType="pubmed">30947333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burch H.B., Lahiri S., Bahn R.S., Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp. Eye Res. 1997;65:311–316. doi: 10.1006/exer.1997.0353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/exer.1997.0353</ArticleId>
            <ArticleId IdType="pubmed">9268599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Steensel L., Paridaens D., van Meurs M., van Hagen P.M., van den Bosch W.A., Kuijpers R.W., Drexhage H.A., Hooijkaas H., Dik W.A. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 2012;97:E400–E408. doi: 10.1210/jc.2011-2697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2011-2697</ArticleId>
            <ArticleId IdType="pubmed">22238384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y.E. Non-smad signaling pathways of the TGF-beta family. Cold Spring Harb. Perspect. Biol. 2017;9:a022129. doi: 10.1101/cshperspect.a022129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a022129</ArticleId>
            <ArticleId IdType="pmc">PMC5287080</ArticleId>
            <ArticleId IdType="pubmed">27864313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie L., Law B.K., Chytil A.M., Brown K.A., Aakre M.E., Moses H.L. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia. 2004;6:603–610. doi: 10.1593/neo.04241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/neo.04241</ArticleId>
            <ArticleId IdType="pmc">PMC1531665</ArticleId>
            <ArticleId IdType="pubmed">15548370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbera M.J., Puig I., Domínguez D., Julien-Grille S., Guaita-Esteruelas S., Peiro S., Baulida J., Francí C., Dedhar S., Larue L., et al.  Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene. 2004;23:7345–7354. doi: 10.1038/sj.onc.1207990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1207990</ArticleId>
            <ArticleId IdType="pubmed">15286702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang F., Chen Y., Ren S., Li Z., Sun K., Xing Y., Zhu Y., Piao D. Cyclovirobuxine D inhibits colorectal cancer tumorigenesis via the CTHRC1AKT/ERKSnail signaling pathway. Int. J. Oncol. 2020;57:183–196. doi: 10.3892/ijo.2020.5038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2020.5038</ArticleId>
            <ArticleId IdType="pmc">PMC7252468</ArticleId>
            <ArticleId IdType="pubmed">32319595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saifi M.A., Shaikh A.S., Kaki V.R., Godugu C. Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. J. Cell Physiol. 2022 doi: 10.1002/jcp.30717. online ahead of print.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.30717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Zhang J., Zhao J., Chen S., Zhou T., Xu J. Treatment of severe acute pancreatitis and related lung injury by targeting gasdermin D-mediated pyroptosis. Front. Cell Dev. Biol. 2021;9:780142. doi: 10.3389/fcell.2021.780142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2021.780142</ArticleId>
            <ArticleId IdType="pmc">PMC8632453</ArticleId>
            <ArticleId IdType="pubmed">34858995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartalena L., Baldeschi L., Dickinson A., Eckstein A., Kendall-Taylor P., Marcocci C., Mourits M., Perros P., Boboridis K., Boschi A., et al.  Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18:333–346. doi: 10.1089/thy.2007.0315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2007.0315</ArticleId>
            <ArticleId IdType="pubmed">18341379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartalena L., Baldeschi L., Boboridis K., Eckstein A., Kahaly G.J., Marcocci C., Perros P., Salvi M., Wiersinga W.M. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur. Thyroid J. 2016;5:9–26. doi: 10.1159/000443828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000443828</ArticleId>
            <ArticleId IdType="pmc">PMC4836120</ArticleId>
            <ArticleId IdType="pubmed">27099835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartalena L., Kahaly G.J., Baldeschi L., Dayan C.M., Eckstein A., Marcocci C., Marino M., Vaidya B., Wiersinga W.M. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur. J. Endocrinol. 2021;185:G43–G67. doi: 10.1530/EJE-21-0479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-21-0479</ArticleId>
            <ArticleId IdType="pubmed">34297684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y., Wu Y., Huang Y., Fang S., Li Y., Sun J., Zhou H. Immunological features of paranasal sinus mucosa in patients with graves’ orbitopathy. Front. Endocrinol. 2020;11:621321. doi: 10.3389/fendo.2020.621321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2020.621321</ArticleId>
            <ArticleId IdType="pmc">PMC7902916</ArticleId>
            <ArticleId IdType="pubmed">33643223</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
